KSHB: Are Weight-Loss Drugs the Future of Medicine? Here's What KC-Area Experts Had to Say

 1 minute

A new class of drugs have taken over the market: some treat type 2 diabetes, and some focus on weight loss. Semaglutide (commonly known as Ozempic or Wegovy) and Tirzepatide (commonly known as Mounjauro or Zepbound) can cost more than $1,000 a month.

Yet many of the patients who would benefit most from these drugs can’t get them because of cost or supply issues.

KSHB talked Dr. Mikhail Kosiborod, cardiologist and vice president of research at Saint Luke's Mid America Heart Institute who has been studying the drugs, and one of his patients, Jacque Long, about the impact of these new medications for those who need it most.